Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 27.22 USD -0.62% Market Closed
Market Cap: 10.5B USD

Wall Street
Price Targets

MRNA Price Targets Summary
Moderna Inc

Wall Street analysts forecast MRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRNA is 51.1 USD with a low forecast of 20.2 USD and a high forecast of 222.6 USD.

Lowest
Price Target
20.2 USD
26% Downside
Average
Price Target
51.1 USD
88% Upside
Highest
Price Target
222.6 USD
718% Upside
Moderna Inc Competitors:
Price Targets
SLNO
Soleno Therapeutics Inc
39% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
62% Upside
PYC
PYC Therapeutics Ltd
218% Upside
BIOCON
Biocon Ltd
26% Upside
NGNE
Neurogene Inc
194% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
75% Upside
QURE
Uniqure NV
164% Upside
BIOPOR
Bioporto A/S
170% Upside

Revenue
Forecast

Revenue Estimate
Moderna Inc

For the last 7 years the compound annual growth rate for Moderna Inc's revenue is 48%. The projected CAGR for the next 3 years is 1%.

48%
Past Growth
1%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Moderna Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Moderna Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MRNA's stock price target?
Price Target
51.1 USD

According to Wall Street analysts, the average 1-year price target for MRNA is 51.1 USD with a low forecast of 20.2 USD and a high forecast of 222.6 USD.

What is Moderna Inc's Revenue forecast?
Projected CAGR
1%

For the last 7 years the compound annual growth rate for Moderna Inc's revenue is 48%. The projected CAGR for the next 3 years is 1%.

Back to Top